Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...
Being a multiple myeloma care partner involves significant logistical and emotional challenges. Panelists acknowledge the ...
Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.
FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple ...
DARZALEX FASPRO ® U.S. Prescribing Information. 2 Johnson & Johnson Innovative Medicine. DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet ...
Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat patients early after relapse.
(RTTNews) - Drug major Johnson & Johnson (JNJ) announced Tuesday that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) ...
FDA approved DARZALEX FASPRO for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Certain ...
The US Food and Drug Administration (FDA) yesterday approved daratumumab and hyaluronidase-fihj – trade name Darzalex Faspro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results